CG Bio Group announced on May 6 that it has launched a new acellular dermal matrix (ADM)-based product, Reallo Inject Fine, on May 1.
Reallo Inject Fine is built on the company’s accumulated human tissue processing technology. It uses ADM material derived from donated human tissue, in which cellular components are removed while preserving the structural properties of the dermal layer.
The new product expands the existing Reallo Inject lineup, offering more segmented options depending on usage purpose and treatment area. Notably, it is designed in a fine particle powder form compared with previous products, improving usability for medical professionals and expanding procedural applications.
Reallo Inject Fine is produced at CG Bio’s Hyangnam Novo Factory, a key facility specializing in human tissue processing and ADM-based product manufacturing. The company said the site supports stable supply through a systematic quality control system.
Distribution will be handled by DNC, a CG Bio Group affiliate. DNC plans to leverage its domestic sales and marketing experience across medical aesthetics products—including botulinum toxin, fillers, and sutures—to expand the market presence of Reallo Inject Fine.
Meanwhile, CG MedTech, another group affiliate, is pushing to scale up production of human tissue grafts and ADM products based on its Seongnam tissue bank infrastructure. The company is also reviewing expansion into the CDMO (contract development and manufacturing organization) business to strengthen group-wide supply capabilities.
CEO Yoo Hyun-seung said the new product reflects the group’s expertise in human tissue processing, adding that the company aims to drive market adoption and growth by leveraging its production infrastructure and distribution network.
CG Bio develops and manufactures human tissue-based medical devices and regenerative medicine materials, focusing on tissue engineering products such as ADM and bone graft substitutes.